BioCytics

Executive Summary

BioCytics is a privately-held biotechnology company focused on developing novel cellular therapies for solid tumors. Founded in 2005 and based in San Diego, the company operates a Human Applications Lab that provides contract development and manufacturing (CDMO) and contract research (CRO) services, alongside a biobanking and biospecimen procurement business. This dual revenue model supports its core mission to accelerate personalized cellular immunotherapies to market. While still in the pre-clinical stage, BioCytics leverages its service arm to generate revenue and build capabilities for its proprietary pipeline, targeting difficult-to-treat solid tumors with novel cell therapy approaches. The company's long-standing presence and diversified business model position it to potentially capitalize on the growing demand for cell therapy manufacturing and personalized immunotherapy solutions.

Upcoming Catalysts (preview)

• Q4 2026IND filing for lead cell therapy candidate targeting solid tumor30% success
• Q3 2026Partnership or licensing deal for CDMO/CRO services with a larger biopharma50% success
• Q4 2026Publication of preclinical data in a peer-reviewed journal demonstrating efficacy of personalized immunotherapy70% success